

" .FUIPEPMPHJD \$PNQBSJTPO PG \*OWBEFS BOI





10. Ledford M, Friedman KD, Hessner MJ, Moehlenkamp C, Williams TM, et al. (2000) A multi-site study for detection of the factor V (Leiden) mutation from JHQRPLF '1\$ XVLQJ D KRPRJHQHRXV LQYDGHU resonance energy transfer (FRET) assay. J Mol Diagn 2: 97-104.
11. INFINITI System Assay for Factor II-V Leiden [directional package insert]. Vista, CA: Autogenomics, Inc; 2012.
12. Galli M, Ruggeri L, Barbui T (1998) Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 91: 1999-2004.
13. /H '7 \*ULI¿Q -+ \*UHHQJDUG -6 OXMPEDU 9 generally applicable tissue factor--dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood 85:1704-1711.
14. \*ULI¿Q 7- +DOO -\* 3UXGHQW -5 6PLWK /0 matrix-assisted laser desorption/ionization mass spectrometry. Proc Natl Acad Sci USA 96: 6301-6306.
15. Kaiser MW, Lyamicheva N, Ma W, Miller C, Neri B, et al. (1999) A comparison of PLEFURWLWHU SODWH ÀXRUHVFHQFH RI HXEDFWHULDO DQG DUFKDHDO VWUXFWXUH VSH 274: 21387-21394.
16. Lyamichev V, Mast AL, Hall JG, Prudent JR, Kaiser MW, et al. (1999) 3RO\PRUSKLVPLGHQWL¿FDWLRQ DQG TXDQWLWDW invasive cleavage of oligonucleotide probes. Nat Biotechnol 17: 292-296.
17. French D, Smith A, Powers MP, Wu AH (2011) KRAS mutation detection in 5DS Ductal cancer by a commercially available gene chip array compares well with Sanger sequencing. Clin Chim Acta 412:1578-1581.
18. %DELFL +DYHU¿HOG (9 %XUUXV -\$ /R]DGD \$ 'DV performance of three commercial platforms for warfarin sensitivity genotyping. Clin Chim Acta 408-414:147-157.

Citation: Weyant GW, Newell JM, Benko FA, Donaldson KJ (2014) A Methodologic Comparison of Invader and Autogenomics INFINITI in Factor-V Leiden and Prothrombin Gene Mutation Testing. J Clin Diagn Res 2: 104. doi: 10.4172/.1000104